Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome
- 13 February 2018
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 84 (6), 1238-1249
- https://doi.org/10.1111/bcp.13548
Abstract
Aims Anti‐CD20 antibodies are increasingly being used to treat idiopathic nephrotic syndrome (INS) in children. While they may allow steroid and calcineurin inhibitor withdrawal, repeated infusions of anti‐CD20 antibodies are often required to maintain remission. Data on their potential toxicity in INS are needed, to consider repeated infusions. Methods We investigated the side effects associated with the use of rituximab (a chimeric antibody; 130 patients) and ofatumumab (a humanized antibody; 37 patients) in children with INS (steroid‐dependent and steroid/calcineurin inhibitor‐dependent disease) treated at a national referral centre over a 9‐year period (400 treatments; follow‐up 1–9 years). Results Infusion reactions were mainly absent in children with steroid‐dependent disease. Rash, dyspnoea, fever, cough and itchy throat (5% and 18% following rituximab and ofatumumab infusion, respectively) were resolved by using premedication with salbutamol. Other short‐term reactions (up to 3 months), including arthritis (2%) and lung injury (1%), were more common with rituximab. Infections were observed 3–9 months following infusion, were similarly common in the two groups and resolved with targeted therapies [antibiotic, fluconazole, immunoglobulins (Igs), etc.]. The number of circulating CD19/20 cells fell to 0 at month 1 and were reconstituted at month 3; circulating IgG antibodies remained within the normal range for 1 year. Tetanus and hepatitis B virus immunization was not modified by either treatment; Epstein–Barr virus and John Cunningham virus activation markers were occasionally observed. Conclusion Overall, the toxicity of anti‐CD20 monoclonal antibodies was limited to post‐infusion side effects in children with more complex disease. The relatively safe profile of anti‐CD20 antibodies supports their use as steroid‐sparing agents in children with INS.Keywords
Funding Information
- Compagnia di San Paolo (ROL9849)
This publication has 46 references indexed in Scilit:
- Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndromeKidney International, 2013
- Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?Pediatric Nephrology, 2012
- Rituximab in Children with Resistant Idiopathic Nephrotic SyndromeJournal of the American Society of Nephrology, 2012
- Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trialAnnals Of The Rheumatic Diseases, 2011
- Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2011
- Rituximab efficiency in children with steroid-dependent nephrotic syndromePediatric Nephrology, 2010
- Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporinePediatric Nephrology, 2010
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in childrenPediatric Nephrology, 2009
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 casesPediatric Nephrology, 2008
- Rituximab‐induced interstitial lung diseaseAmerican Journal of Hematology, 2007